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Original Contributions and Case Studies

Assessment of Methylprednisolone Purging Efficacy on Daudi
Burkitt Lymphoma Cells from Normal Bone Marrow
Nalini Janakiraman, MD,* and Loreen M. Niewenhuis, BSMT*

Studies tm normal htme marrow and Daudi Burkitt lymphoma cells were performed lo delermine lhe
efficacy of selective, in vitro cliemopurging wilh methylprednisolone (MP). Wefmind that MP reduces
Ihe numher of lymphoma cells without significant damage to htme marrow cells. This informalitm
is important hecause we need to improve the exisling in vitro purging regimens used lo cleanse
autologous marrows of metastatic disease before transplantation inlo cancer paiienis who have
received high-dose chemotherapy. Normal human hone marrow (NBM) and Daudi lymphoma cells
were trealed in paraUel with various purging regimens. NBM death was evaluated using stft-agar
cuhure. while Daudi cell death was evaluated using one-week liquid culture. A protocol of 2.0 mg/mL
( f MP for four hours demonstrated optimal selectivity. When treatment was followed hy cryopreservation. a 1.7 log purge tf Daudi cells was increased to 2.3 logs while preserving 36% tf
commined NBM precursors. We repealed these experiments on a simulated contaminated marrow lo
model closely the mixture tf normal and malignani celts found in advanced, metastatic disease We
evaluated this mixed system by flow cytometric imniunoanalysis using the two-color CDI0/CD20
markers to detect residual, viable Daudi cells. Our initial results were reproducible in this mixed-cell
svstem. further supporting the evidence for effective in vitro purging trf hone marrow using MP.
(Henry Ford Hosp Med J 1991:39:l 17-22)

A

utologous bone marrow transplant (ABMT) employed to
circumvent the hematopoietic toxicities associated with
high-dose chemotheiapy offers hope to many cancer patients
with advanced or relapsed disease. The presence of metastases
to the marrow, however, excludes patients from undergoing this
procedure. While most attention has been paid to purging leukemic blasts from normal bone marrow (NBM) (1-3), much less
work has been done with lymphoma purging. Over 40,000 new
non-Hodgkin's lymphoma cases are diagnosed annually (4) and
a majority of these patients will have bone marrow metastases
(5-7). Bone marrow contaminatio.i excludes these patients from
undergoing A B M T after high-dose chemotherapy—a potentially curative treatment (8). An effective in vitro purging regimen is needed to make this therapy available to patients whose
best olher hope for cure is allogeneic marrow transplant with its
limitations of matched-donor availability and graft versus host
disease (9). Many approaches have been investigated to purge
the marrow of contaminating tumor cells, including immunologic (10-12), pharmacologic ( I ) , physical separation (13,14),
and combination techniques (15,16), among others (17-19).
We chose to evaluate in vitro purging using methylprednisolone (MP). Steroids act on cells in several ways; they control the
rate of protein synthesis in lymphoid cells (20), impair antigen
recognition and cell-to-cell cytotoxicity by lymphocytes (21),
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suppress interleukin-2 and y-interferon production, and suppress T-cell proliferation and the generation of cytotoxic T-cells
(22). Steroid hormones and their derivatives are used in virtually
all combination chemotherapy regimens for both Hodgkin's and
non-Hodgkin's lymphomas (23.24). MP possesses antilymphocytotoxic activity in vivo with minimal toxicity to NBM (25).
In the initial study treating NBM and Daudi cells in parallel,
soft-agar cultures were used to assess N B M toxicity, and oneweek liquid cultures were used to assess the effects on clonogenic Daudi cells. For the liquid cultures, both control and
treated cells were put into Daudi cell growth media and growth
was monitored over a one-week period by cell counts and trypan
blue percent viability. These cultures permitted assessing the
clonogenic potential of the malignant cells as compared to the
control cultures. These assays were carried out after MP treatment alone or after MP treatment followed by cryopreservation
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and thawing. The cryopreservation step allowed us to evaluate
any additional kill of the MP-weakened Daudi cells from the
stress of the freezing/thawing process. Once an optimal treatment protocol was formulated, we proceeded to test the treatment without cryopreservafion on a simulated contaminated
marrow (SCM). Our analysis at this stage was via determination
of colony-forming units-granulocyte macrophage (CFUs-GM)
for NBM precursors and semi-quantitafion by flow cytometric
immunoanalysis for residual Daudi cells utilizing dual CDIO/
CD20 antigens.

Methods
Normal Bone Marrow: Bone marrow was obtained after informed writien consent from various oncology patients undergoing the procedure as part of their staging workup. Bone marrow was collected onto tissue culture media with preservativefree heparin, diluted with RPMI 1640, and passed over ficoll
(1.077 g/cm') to isolate the mononuclear cells for treatment.
Cell Line: Daudi Burkitt lymphoma cells were obtained from
American Type Culture Collection (ATCC. Rockville. MD) and
maintained in RPMI 1640 with 10% fetal calf serum (FCS) with
twice weekly passages. The characteristics ofthis cell line have
been described previously (26). Cells were used in log phase of
division, two to three days after cutting back and feeding.
Drugs: MP was obtained from the Upjohn Company (Kalamazoo, MI), and all dilutions were made with RPMI using 5%
FCS immediately prior to treatment of cells.
Treatment: MP was u.sed at a concentration of 0.25, 0.5. 1.0,
1.5, 2.0, 2.5, and 3.0 mg/mL and for treatment times of 2. 4, 8.
and 24 hours. All cellular concentrations during treatment were
5x10^ cells/mL. Specimens were incubated for the treatment
period at 37° C with 5% CO3 and no shaking afterthe initial mix.
After treatment, specimens were centrifuged, diluted, and plated
in soft-agar cultures. Daudi cells were processed similariy, then
placed in 10 mLof RPMI plus 10% FCS for 7-day liquid culture
analysis.
NBM committed progenitor assays
CFU-GM: Using an inverse microscope, colonies of 40 or
more cells were .scored on day 14 of the plated cultures of NBM
cells employing a modification of the technique previously described (27),
Mixed Progenitor Assay: CFU-GM. colony-forming unitgranulocyte. erythroid, macrophage, megakaryocyte, and burstforming unit-erythroid were asses.sed simultaneously in amethylcellulose matrix system by an established method (28).
Liquid Culture: Daudi clonogenicity or death was assessed
over 7 days while the liquid cultures were maintained at 37° C
with 5% COj. Cell counts and percent viability by trypan blue
dye exclusion test were determined manually at time points 1
hour and days 1, 3. and 7 posttreatment. Cultures were considered negative for viable cells when 1,000 scanned cells were
nonviable on day 7.
Cryopreservation: Some Daudi samples were treated as described, then cryopreserved, quickly thawed, and placed in a liquid culture for 7-day analysis as described above.
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SCM Treatment: NBM mononuclear cells were isolated over
ficoll. After counting, 30% Daudi cells were added to simulate a
contaminated marrow. Treatment with 2.0 mg/mL MP for 4
hours was carried out at 37° C/5% CO., and processed as before.
A sample was taken for cell count and soft-agar culture plating,
and the remaining cells were put inlo liquid culture for 24 hours
before further analysis. After 24 hours, cell counts for viability
were performed on a portion ofthis specimen, and the remainder
was prepared for flow cytometric immunoanalysis.
Labeling for Flow: The dual tags CDIO withfluoresceinisothiocyanate and CD20 with phycoerythrin were used to label the
Daudi cells in the SCM. These antigenic markers are found on
more mature cells and therefore produce little marking on the
NBM cells. The treated SCM was washed twice with phosphatebuffered saline and subsequently passed over ficoll to remove
all dead cells. Cells at the interface were labeled according tothe
manufacturer's instructions (Becton-Dickinson, Mountainview
CA).
Fl ow Cytometric Analysis: The samples were analyzed on a
Coulter Epics 'V system flow cytometer (Coulter Electronics,
Inc, Hialeah, FL) with a Coherent Innova 90-5 lon Argon laser.
The photo multipliers were calibrated using dual-stained beads;
red and greenfluorescencepeaks were put into consistent channels before each run. Two-dimensional graphs of log red fluorescence versus log greenfluorescencewere used to analyze the
specimens for residual Daudi cells, which were dual-stained.
Statistical Analysis: The parallel studies (NBM and Daudi)
were individually analyzed using the Bonferroni multiple comparison analysis method of two-sided paired t tests. Flow cytometric data were used to calculate log reduction but were not
statistically analyzed due to its semi-quantitative nature. Normal progenitor recovery, calculated as mean ± SD from all
plates for each treatment point, served as control values.

Results
Parallel studies
Effect on NBM suspension—Dose, time-course response
curves of MP were established for NBM cells using the soft-agar
culture assay CFU-GM as the gauge for the system (Fig I). Duration of treatment was more critical than drug concentration as
represented by the three curves. A 4-hour exposure to MP did
not produce significant CFU-GM depletion at any drug concentration. The 8-hour treatment produced significant depletion of
colonies at the 1.5 mg/mL concentration; the 24-hour treatment
data are more variable due to a decrease in the number of colonies in the 24-hour control specimen.
Effect on Daudi Burkitt's lymphoma cell llne—Identical
treatments were performed on the Daudi cells, and cell counts
with trypan blue dye exclusion viability done periodically during one-week liquid culture. Survival was compared to that of
control cells at day 7 after treatment. A statistically significant
depletion in Daudi cells was seen at all levels andtimecourses
e.xcept 4 hours with 0.25 or 0.50 mg/mL MP (Fig 2).
The best differentiation between Daudi cell death and CFUGM preservation was achieved with a drug concentration of 2.0
mg/mL MP with treatment for 4 hours. This drug regimen fol-
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Table
Effect of Methylprednisolone Treatment With and Without
Cryopreservation on Normal Human Progenitors*

Non-cryopre served
control!"
Non-cryopreserved
MP-treated?
Cryopreserved
controlt
Ciyopreserved
MP-lreated;|;

80
60
40
20— I —

,25

0,5

Concentration

-r
1,0

1,5

— I —

2.0

~ l —
2,5

—1—

3,0

of Methylprednisolone (mgim\

CFU-GM

BFU-E

CFU-GEMM

23 ± 4
(100%)
24 ±5
(104%)
18 ± 3
(78%)
I6±4
(70%)

162±58
(100%)
74 + 61
(46%)
107 ±40
(66%)
58 ± 36
(.36%)

5+2
(100%)
4±2
(80%)
5+ 1
(100%)
4± 1
(80%,)

•'•Methylprednisolone treatment = 4,0 mg/mL for 4 lours.
•rN = 3,
tN = 7,
Note: CFIJ per 2 x lO^''cells.
Numbers in parentheses indicate percent of non-cryopreserved conlrol,
CFU-GM = colony-forming unit-granulocyte macrophage: BFU-E = burst-forming
unil-erythroid; CFU-GEMM - colony-forming unil-granuloeyte, erythroid, macrophage,
megakaryocyte: MP - methylprednisolone.

Fig 1—Percent survival of CFU-GM colonies in hone marrow
specimens treated with different concentrations and for different time courses with methylprednisolone. Bars represent standard deviation (n =3). Where there are no bars the SD was less
than or equal to 10%.

lowed by cryopreservation was then used in the Daudi treatment
and the SCM treatment experiments.
Treatment plus cryopreservation—Cryopreservation following treatment with 2.0 mg/mL of MP for 4 hours was found lo
increase the log kill of Daudi cells from an average of 1.7 (range
1.5-1.9) to 2,3 logs (range 2.0-2.6). This effect is thought to be
due to the increased stress on MP-weakened cells. NBM progenitor recovery was also determined postcryopreservation (Table). We performed the mixed-progenitor assay in methylcellulose to ascertain any selective depletion of one type of progenitor.
SCM studies—In the SCM experiment we were again able to
recover CFU-GM colonies posttreatment. Flow cytometric immunoanalysis yielded a distinct population of CDI0/CD20-labeled Daudi cells. Normal marrows had less than 1.5% positive
dual-staining cells, and this background amount was subtracted
from each SCM control (SCMC) and SCM treatment (SCMTX)
specimen (Fig 3). These background-corrected percentages
were multiplied by the 10.000 cells counted per sample to compute the actual number of Daudi cells per 10,000 in both the
SCMC and SCMTX specimens (Fig 4). Log reduction was calculated by the equation:
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Fig 2—Daudi cell death as ccmipared to the control after seven
days in culture following the specified treatment regimens with
methylprednisolone.

#Daudi cells in SCMC - #background
#Daudi cells in SCMTX - #backaround

The average log reduction in these samples assayed 24 hours
posttreatment was 1.4 logs. We allowed an intervening 24-hour
period between treatment and flow cytometry due to the slow
nature of cell death following treatment with MP. The largest
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decline in cellular viability occurs in the first 24 hours following
treatment.

Discussion
There is clearly a need for a selective and effective method of
purging contaminating tumor cells from bone marrow while pre-

Purging Lymphoma Cells wilh MP—Janakiraman & Niewenhuis

119

\ze

130

140

158

lee

l l l l l l l l l l l l l l l l l l l l l l l l l ,

s

s 4
128
138
|48
158
16
J—l-Jt_l—l_l-J_t l..,l._l._l._t_t_J_J_LJL-t_t_L

2?

L
I
R
F
L

2

JT)

1-

» 4
1 8 " ' I l 8 8 '

tdt'iiFh

Fig 3—CDl()/CD2() staining if Daudi cells and normal hone
marrow. LIRFL = log Integrated red fluorescence ofthe phxcoerythiin-lahelcd CD20 monoclonal antibody: LIGFL = log Integrated green fluorescence tf the fluorescein isothiocyanatelabeled CDIO monoclonal antibody. Quadrant #2 is where anv
dual-stained, CDIO and CD20 dual-positive, cells will be detected. Top: Daudi cells dual-staining over 95%, BotU>m: Normal htme marrow stained with .same reagents showing less than
1.5% background dual-staining population.

serving the capability for engraftment, Chemopurging agents without myelosuppressive activity are the most promising means of
in vitro purging. Many steroid hormones and their derivatives
known for lymphocytotoxicity and lack of myelosuppression
are used in combination chemotherapy for lymphoma (24).
Our,study entailed two phases. First, parallel studies on NBM
and Daudi Burkitt lymphoma cells were performed to determine
the efficacy of MP to kill the tumor ceil line selectively. The
studies demonstrated the effect of treatment alone and treatment
coupled wilh subsequent cryopreservation. Marrow mononu-

120

Henry Ford Hosp Med J—Vol 39, No 2, 1991

clear cells and Daudi cells were treated in parallel with concentrations of the drug ranging from 0.25 to 3.0 mg/mL for a durafion of 4, 8, or 24 hours. Daudi cell survival was evaluated by periodic cell counts with trypan blue viability using one-week liquid cultures. MP demonstrated optimal selectivity for purging
Daudi lymphoma cells without causing significant damage to
NBM precursors using a treatment protocol of 2.0 mg/mL for 4
hours. This protocol eliminates an average 1.7 logs of Daudi
cells when used alone and an average 2.3 log reduction when
followed immediately by cryopreservation and thawing, while
there is little detectable damage to NBM precursors as measured
by CFU-GM assays. Unlike the murine model, there is no "stem
cell" assay for human bone marrow. Therefore, it is difficult to
assess the engraftment potential of any purged manrow short of
actual in vivo hematopoietic reconstitution. We used in vitro
soft-agar culture assays for committed hematopoietic progenitors to appraise the NBM cell status. CFU-GM assay results
have correlated with engraftment potential in some studies (29),
while no correlation was found in others (30). For example, using in vitro, high-dose (80 pg/mL or higher) 4-hydroperoxycyclophosphamide purging, hematopoietic reconstitution was produced in vivo, although no CFU-GM colonies were recovered
(31).
The second phase ofthis ,study involved using our protocol on
a SCM, a mixture of 70% marrow mononuclear cells and 30%
Daudi cells. This mixed-cell system was evaluated by the CFUGM as,say and semi-quantitation by flow cytometric immunoanalysis for the dual markers CDIO and CD20, which are found
on the Daudi cells but rarely together on NBM cells. The CDIO
and CD20 markers are found together only on the pre-B lymphocyte stage of normal cells. Once the cell differentiates into a
resfing B-cell, it loses the CDIO cluster antigen, and when activated it is negative for both CDIO and CD20. The Daudi cells,
however, stain uniformly CDI0-I-/CD20-F. This unusual combination of antigens makes flow cytometry an attractive method
for evaluating purging efficiency. Our initial results were reproducible in the more realistic setting of SCM. The minimum average reduction of Daudi cells in these SCM samples 24 hours
posttreatment (to allow for slow cell death due to the treatment)
was 1.4 logs as detected by flow cytometry, with no significant
loss of NBM committed precursors as detected by CFU-GM. A
longer time course could not be studied with this system due to
the demise of NBM in liquid culture. The sensitivity of flow cytometric immunoanalysis is approximately 1% of a population
of cells. The percentages become firmer as we increase the
number of cells counted, but the .sensitivity of the method does
not increase. Using flow cytometry, we were able to utilize an
authentic model of tumor-involved marrow; the malignant cells
in SCM were not altered in any way prior to admixing with
NBM.
More aggressive regimens should be explored, including
combination treatments of MP with other synergistic drugs. Trials with actual patient bone marrow with contaminating tumor
are anticipated. Such marrow can be evaluated for residual tumor cells using other sensitive methods, e.g., prelabeling with
Hoestch 33.342 stain (32,33) or limiting dilution analysis (34).
Polymerase chain reaction could be applied as a very sensitive

Purging Lymphoma Cells w ith MP—Janakiraman & Niewenhuis

method to detect residual occult malignant cells (35,36). This
application, however, would be restricted to detecting those tumors with a known, consistent genetic marker.
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